JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Improving Participation in Colorectal Cancer Screening: a Randomised Controlled Trial of Sequential Offers of Faecal then Blood Based Non-Invasive Tests
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Improving Participation in Colorectal Cancer Screening: a Randomised Controlled Trial of Sequential Offers of Faecal then Blood Based Non-Invasive Tests
Symonds, Erin L; Pedersen, Susanne; Cole, Stephen R; Massolino, Joseph; Byrne, Daniel; Guy, John; Backhouse, Patricia; Fraser, Robert J; LaPointe, Lawrence; Young, Graeme P;
  PDF(new window)
 Abstract
Background: Poor participation rates are often observed in colorectal cancer (CRC) screening programs utilising faecal occult blood tests. This may be from dislike of faecal sampling, or having benign bleeding conditions that can interfere with test results. These barriers may be circumvented by offering a blood-based DNA test for screening. The aim was to determine if program participation could be increased by offering a blood test following faecal immunochemical test (FIT) non-participation. Materials and Methods: People were invited into a CRC screening study through their General Practice and randomised into control or intervention (n
 Keywords
Colorectal cancer;screening;faecal immunochemical test;methylated blood test;participation;FOBT;
 Language
English
 Cited by
1.
Protocol Outlines for Parts 1 and 2 of the Prospective Endoscopy III Study for the Early Detection of Colorectal Cancer: Validation of a Concept Based on Blood Biomarkers, JMIR Research Protocols, 2016, 5, 3, e182  crossref(new windwow)
2.
Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer, The American Journal of Gastroenterology, 2017, 112, 7, 1016  crossref(new windwow)
 References
1.
Adler A, Geiger S, Keil A, et al (2014). Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol, 14, 183. crossref(new window)

2.
AIHW 2014. National Bowel Cancer Screening Program monitoring report: 2012-13., Canberra, Australian Institute of Health and Welfare Canberra.

3.
Benning TM, Dellaert BG, Dirksen CD, et al (2014). Preferences for potential innovations in non-invasive colorectal cancer screening: A labeled discrete choice experiment for a Dutch screening campaign. Acta Oncol, 53, 898-908. crossref(new window)

4.
Bresalier RS, Kopetz S, Brenner DE (2015). Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test? Dig Dis Sci, 60, 664-71. crossref(new window)

5.
Cole SR, Gregory T, Whibley A, et al (2012). Predictors of Re-participation in Faecal Occult Blood Test-Based Screening for Colorectal Cancer. Asian Pac J Cancer Prev, 13, 5989-94. crossref(new window)

6.
Cole SR, Tucker GR, Osborne JM, et al (2013). Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust, 198, 327-30. crossref(new window)

7.
Cole SR, Young GP, Byrne D, et al (2002). Participation in screening for colorectal cancer based on a faecal occult blood test is improved by endorsement by the primary care practitioner. J Med Screen, 9, 147-52. crossref(new window)

8.
Cole SR, Young GP, Esterman A, et al (2003). A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen, 10, 117-22. crossref(new window)

9.
Cole SR, Zajac I, Gregory T, et al (2011). Psychosocial variables associated with colorectal cancer screening in South Australia. Int J Behav Med, 18, 302-9. crossref(new window)

10.
DeBourcy AC, Lichtenberger S, Felton S, et al (2008). Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening. J Gen Intern Med, 23, 169-74. crossref(new window)

11.
deVos T, Tetzner R, Model F, et al (2009). Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem, 55, 1337-46. crossref(new window)

12.
Fox A, Tietze PH, Ramakrishnan K (2014). Anorectal conditions: hemorrhoids. FP Essent, 419, 11-9.

13.
Greiner KA, James AS, Born W, et al (2005). Predictors of fecal occult blood test (FOBT) completion among low-income adults. Prev Med, 41, 676-84. crossref(new window)

14.
Hardcastle JD, Chamberlain JO, Robinson MH, et al (1996). Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet, 348, 1472-7. crossref(new window)

15.
Hol L, Kuipers EJ, van Ballegooijen M, et al (2012). Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer, 130, 2096-102. crossref(new window)

16.
Mandel JS, Bond JH, Church TR, et al (1993). Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med, 328, 1365-71. crossref(new window)

17.
Marshall DA, Johnson FR, Phillips KA, et al (2007). Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health, 10, 415-30. crossref(new window)

18.
Miles A, Rainbow S, von Wagner C (2011). Cancer fatalism and poor self-rated health mediate the association between socioeconomic status and uptake of colorectal cancer screening in England. Cancer Epidemiol Biomarkers Prev, 20, 2132-40. crossref(new window)

19.
Mitchell SM, Ross JP, Drew HR, et al (2014). A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer, 14.

20.
Osborne J, Wilson C, Moore V, et al (2012). Sample preference for colorectal cancer screening tests: Blood or stool? OJPM, 2, 326-31. crossref(new window)

21.
Pedersen S, Symonds E, Baker R, et al (2015a). Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer, In press.

22.
Pedersen SK, Baker RT, McEvoy A, et al (2015b). A two-gene blood test for methylated DNA sensitive for colorectal cancer. PLoS One, 10, 125041.

23.
Senore C, Ederle A, Benazzato L, et al (2013). Offering people a choice for colorectal cancer screening. Gut, 62, 735-40. crossref(new window)

24.
Symonds E, Young G, Osborne J, et al (2015). Comparison of a methylated two-gene (BCAT1-IKZF1) blood test to FIT for detection of colorectal neoplasia. Gastroenterology, 148, 746.

25.
van Dam L, Kuipers EJ, Steyerberg EW, et al (2013). The price of autonomy: should we offer individuals a choice of colorectal cancer screening strategies? Lancet Oncol, 14, 38-46. crossref(new window)

26.
Worthley DL, Cole SR, Esterman A, et al (2006). Screening for colorectal cancer by faecal occult blood test: why people choose to refuse. Intern Med J, 36, 607-10. crossref(new window)

27.
Zorzi M, Fedeli U, Schievano E, et al (2014). Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut.